Cumberland Pharmaceuticals Inc. enters into a definitive agreement to acquire the FDA-approved oncology-supportive care medicine SANCUSO® from Kyowa Kirin Inc. the U.S. affiliate of Japan-based Kyowa Kirin Co., Ltd. Under the terms of the agreement, Cumberland will acquire U.S. rights to SANCUSO and will assume full commercial responsibility for the product – including its marketing, promotion, distribution, manufacturing and medical support activities. Net sales of the brand in the U.S. were over $14 million in 2020. The financial terms of the acquisition include a $13.5 million payment to Kyowa Kirin upon closing, up to $3.5 million in milestones and tiered royalties of up to 10% on U.S. net product sales.

Kyowa Kirin will retain international rights, continuing to deliver the product to address oncology patients' needs throughout the rest of the world.